CN104306615A - 一种治疗冠心病的药品及其制备方法 - Google Patents
一种治疗冠心病的药品及其制备方法 Download PDFInfo
- Publication number
- CN104306615A CN104306615A CN201410521251.4A CN201410521251A CN104306615A CN 104306615 A CN104306615 A CN 104306615A CN 201410521251 A CN201410521251 A CN 201410521251A CN 104306615 A CN104306615 A CN 104306615A
- Authority
- CN
- China
- Prior art keywords
- medicine
- twice
- preparation
- water
- granulate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 83
- 229940079593 drug Drugs 0.000 title claims abstract description 23
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 23
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000012567 medical material Substances 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 19
- 241000628997 Flos Species 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 9
- 230000003179 granulation Effects 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 206010008479 Chest Pain Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000007613 Shoulder Pain Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗冠心病的药品，由川芎、红花、地骨皮、槟榔、牡丹皮、枸杞六味中药组成，该中药组合物可以制备成药品，实验研究表明，本发明药品能够有效治疗冠心病。
Description
技术领域
本发明属于中药领域。具体涉及到一种制备治疗冠心病的组合物及其制备方法。
背景技术
冠心病，指由于脂质代谢不正常，血液中的脂质沉着在原本光滑的动脉内膜上，在动脉内膜一些类似粥样的脂类物质堆积而成白色斑块，称为动脉粥样硬化病变。这些斑块渐渐增多造成动脉腔狭窄，使血流受阻，导致心脏缺血，产生心绞痛。
冠心病是一种由冠状动脉硬化性(动脉粥样硬化)或动力性(血管痉挛)狭窄或阻塞引起心肌缺血缺氧或坏死的心脏病，亦称缺血性心脏病。
西医认为动脉粥样硬化(AS)发生机制有3种比较公认的学说：①脂质浸润学说：AS的形成是血管壁对血浆中浸入的脂质的一种反应性病变。②血栓形成学说AS的形成是由于局部附壁血栓嵌入内膜的结果。③损伤反应学说AS实质上是一种炎症过程。增厚的病灶是血管壁内结缔组织对致炎因素的～种增生性反应。实质上，上述3种学说是AS发生，发展的不同过程。冠心病的易患因素：①高血压，②高脂血症，⑦吸烟，④糖尿病，⑤肥胖，⑥家族史等。随着人们生活水平的提高、饮食结构的改变、人中老龄化以及紧张的工作压力，冠心病的发病率逐年增高
中医认为冠心病属于中医胸痹。本病多由素体阳虚寒邪内侵、或饮食劳逸、情志失调、年老体衰、瘀血痰饮或久嗜烟酒等原因引起。胸居阳位，宜清旷而忌邪侵。若胸阳不振；寒邪侵袭或阳虚水寒上攻；或寒痰血瘀上乘，均能导致“阴乘阳位”痹阻气机发为“胸痹”,该病是一种严重危害人类健康的常见病猝死率极高，占人口死亡数是1/3以上，是人类生命的一大杀手。
目前，治疗冠心病的药物种类很多，大多是采用西药治疗，治标不治本。其治疗途径多以采用扩冠和减慢心率的药物，提高心肌供氧 和降低心肌耗氧，从而减轻病情症状。但是，这些药物虽然能从一定程度上缓解病症，当始终存在着伤阴、耗气等缺陷。中药治疗虽然原料来源广，价格便宜，副作用小，但是现有的中药制剂存在疗效不确切、治愈率低等不足。
发明内容
本发明目的就是为了弥补已有技术的缺陷，深入研究冠心病的发病机理的基础上，提供一种制备治疗冠心病的药品及其制备方法。本发明在临床应用中安全性良好，未发现任何不良反应。
本发明的药品的原料药川芎、红花、地骨皮、槟榔、牡丹皮、枸杞六味中药组成。
本发明的药品的原料的重量比例为：川芎10-20g、红花8-15g、地骨皮20-40g、25-30g、槟榔6-15g、牡丹皮10-30g、枸杞10-20g。
本发明的药品的原料的重量优选为：川芎15g、红花10g、地骨皮25g、槟榔10g、牡丹皮20g、枸杞15g。
本发明的所述药品的原料的重量比例优选为：川芎15g、红花10g、地骨皮30g、槟榔8g、牡丹皮15g、枸杞15g。
本发明所述药品的原料的重量比例优选为：川芎20g、红花8g、地骨皮20g、槟榔10g、牡丹皮30g、枸杞15g。
本发明药品的活性成分制备方法，由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分。
本发明药品的制剂剂型为胶囊剂、片剂、丸剂、颗粒剂、口服液、泡腾片或保健饮料。
本发明胶囊剂的制备方法由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液1-5倍重量的淀粉、糊精或乳糖中的一种或两种，采用稠膏制粒法，进行制粒，在50-70℃下干燥，整粒，装胶囊，既得胶囊剂。
本发明片剂的制备方法有以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒：取步骤(2)的浓缩液，加入浓缩液1-5倍重量的淀粉、糊精或乳糖中的一种或两种，采用稠膏制粒法，进行制粒，在50-70℃下干燥，整粒，得颗粒备用；
(4)压片：去步骤(3)所得颗粒，加入颗粒重量0.5-1％的硬脂 酸镁，混合均匀，压片，既得片剂。
优选的本发明胶囊剂制备方法，由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液3倍重量的淀粉，采用稠膏制粒法，进行制粒，在65℃下干燥，整粒，装胶囊，既得胶囊剂。
优选的本发明片剂制备方法，由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液3倍重量的淀粉，采用稠膏制粒法，进行制粒，在68℃下干燥，整粒，装胶囊，既得胶囊剂。
本发明中，川芎：味苦、性寒，有清热燥湿、泻火解毒、止血、安胎等功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。
红花：辛，温。入心、肝经。活血通经，去瘀止痛。治经闭，癥瘕，难产，死胎，产后恶露不行、瘀血作痛，痈肿，跌扑损伤。
地骨皮：甘，寒，临床用于治疗高血压，糖尿病。
槟榔：苦，辛，温。归胃、大肠经。治杀虫消积，行气，利水，截疟。《药性论》：“宣利五脏六腑壅滞，破坚满气，下水肿，治心痛，风血积聚。”
牡丹皮：苦、辛，微寒。归心、肝、肾经。功能与主治：清热凉血，活血化瘀。
枸杞：甘，平。滋肾，润肺，补肝，明目。治肝肾阴亏，腰膝酸软，头晕，目眩，目昏多泪，虚劳咳嗽，消渴，遗精。
本发明的优点是：
本发明中药经科学合理配伍，使各药物的功效产生协同作用，调节心脏功能，对于治疗冠心病具有很好的疗效，安全可靠，副作用小。
实施例:
具体实施方式
下述实施例用于举例说明本发明药物的制备，但其不能对本发明的范围构成任何限制。
实施例1：
为了便于本发明药品的应用，将该药品制备成胶囊剂：
原料药配比：川芎15g、红花10g、地骨皮25g、槟榔10g、牡丹皮20g、枸杞15g。
制备方法：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液3倍重量的淀粉，采用稠膏制粒法，进行制粒，在65℃下干燥，整粒，装胶囊，既得胶囊剂。
实施例2：
为了便于本发明药品的应用，将该药品制备成片剂：
原料药配比：川芎15g、红花10g、地骨皮25g、槟榔10g、牡丹皮20g、枸杞15g
制备方法：
((1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒：取步骤(2)的浓缩液，加入浓缩液4倍重量的淀粉，采用稠膏制粒法，进行制粒，在65℃下干燥，整粒，得颗粒备用；
(4)压片：去步骤(3)所得颗粒，加入颗粒重量0.5％的硬脂酸镁，混合均匀，压片，既得片剂。
实施例3：
为了便于本发明药品的应用，将该药品制备成胶囊剂：
原料药配比：川芎15g、红花10g、地骨皮30g、槟榔8g、牡丹皮15g、枸杞15g
制备方法：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液2倍重量的乳糖和淀粉的混合辅料，采用稠膏制粒法，进行制粒，在60℃下干燥，整粒，装胶囊，既得胶囊剂，每粒胶囊的含药量大约为原药的2-3g。
实施例4：
为了便于本发明药品的应用，将该药品制备成口服液：
原料药配比：川芎15g、红花10g、地骨皮30g、槟榔8g、牡丹皮15g、枸杞15g。
制备方法：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分；
(3)按照口服液常规的制备方法制备成口服液剂型
实施例6：
为了便于本发明药品的应用，将该药品制备成颗粒剂：
原料药配比：川芎20g、红花8g、地骨皮20g、槟榔10g、牡丹皮30g、枸杞15g。
制备方法：按常规制剂方法制成颗粒
7、典型病例：
病例1，张某，男，主诉心前区闷痛，气短，反复发作3年并逐渐 加重，患者心前区闷痛，每天发作2～3次，活动、劳累或受冷后加重。服用复方丹参滴丸可缓解。常伴有头晕、周身疲乏、双下肢沉重、血压18/12kPa，心律齐，率86次/min，舌质暗边尖有瘀点，口唇色暗，苔白，脉弦细。心电图检查：T波、I、avL、V4，V5低平，ST段V7、V8呈水平下移0.1mv。超声心动图检查有冠心病改变。血脂检查，胆固醇6.3mmol/L，甘油三脂2.1mmol/L，西医诊断：冠心病、劳累性心绞痛。中医诊断：胸痹、心痛。给予本发明实施例3制备的胶囊，每天两次，每次4粒，服药3d后，心前区闷痛明显减轻，每日发作1～2次可自行缓解，继服1周后，心前区闷痛未发作，疲乏、双下肢沉重感消失，连续服用4周，复查心电图T波I、avL、V4、V5低平较前改善，ST段、V7、V8水平型下移恢复正常。前方随证加减治疗3个月后，症状消失，复查心电图恢复正常，血脂检查胆固醇5.0mmol/L,甘油三脂1.4mmol/L。
病例2，王某，男，68岁。冠心病十多年,现心前区闷痛，常于干活动后发作,伴胸闷心慌，含服硝酸甘油可缓解，服用本发明实施例3制备的药物治疗一个疗程后，症状明显减轻，仅偶有轻微胸痛，继续服药治疗一个月后症状完全消失，随访1年未复发。
病例3，宋某，男，72岁，冠心病史多年，经常发作胸闷、胸痛，每天发作3-4次，含服硝酸甘油不能完全缓解。服用本发明实施例3制备的药物治疗一个疗程后，胸闷、胸痛症状减轻，又继续服用一个疗程，胸痛、胸闷一直未再发作，坚持再服药两个疗程后，胸痛、胸闷一直没有复发，头不晕、腿不麻，自诉症状完全消失，随访未见复发。
病例4，李某，男，56岁，体力活动时有心慌、气短、疲劳和呼吸困难感。长期左肩痛，经一般治疗反复不愈，出现脉搏不齐，过速或过缓。诊断为冠心病。服用本发明发明实施例3制备的药物1个月症 状减轻，左肩痛感消失，服用两个月，体力比以前明显增加，现继续服用。
8、临床试验：本实验治疗组所用的药物为用实施例3制备的胶囊剂。服用方法：每天服用两次，每次4粒，每次9-13克原药。
8.1一般资料：
收集2012年6月自2013年8月共观察冠心病140例，随机分为治疗组和对照组。治疗组75例中，男40例，女35例；年龄6O一95岁；病程15～36年。对照组65例中，男35例，女30例；年龄62～98岁；病程10—34年。两组患者性别、年龄、病程等一般资料比较，差异无统计学意义(P>0.05)，具有可比性。
8.2中医诊断标准参照《中医内科疾病诊疗常规》中的有关标准拟定。胸部闷痛，甚至胸痛彻背；轻者仅感胸闷憋气，呼吸不畅；心电图检查有缺血性改变或运动试验阳性。中医心血瘀阻证候辨证标准参照《中药新药临床研究指导原则》中的有关标准拟定。胸部刺痛或绞痛，痛处固定不移，入夜更甚，时或心悸不宁，舌质紫暗，脉沉弦或结代。
8.3、治疗方法
对照组给予西医常规治疗，单硝酸异山梨酯片10mg，每天1次，口服；美托洛尔12.5mg，每天2次，口服；阿司匹林100mg，每天1次，口服。实验组在对照组治疗的基础上服用实施例3所得胶囊剂。使用方法为：每天服用两次，每次4粒，两组均以治疗15d为1个疗程，每个疗程间间隔15d，6个疗程结束后统计疗效。
8.4、疗效情况判定标准：显效：服用本品一个疗程，心电图显示冠状动脉供血明显改善，不适症状如心悸、胸闷、胸痛、心前区不适、乏力、头晕等症消失或基本消失，或由较重减到轻度，精力及体力明显增加；有效：服用本品一个疗程，心电图示慢性冠状动脉供血改善，不适症状减轻或部分消失，精力及体力增强；无效：服用本品一个疗程，不适症状无变化，甚至加重。
8.5结果：两组临床症状疗效比较：
试验组显效病例为56例，有效病例为17例，无效为2例，显效率与总有效率治疗组分别为74.6％、97％；对照组显效病例为28例，有效病例为20例，无效为2例，其中显效率与总有效率分别为43％、
73.8％，组间比较，差异有统计学意义(见表一)。两组不良反应发生率相似。(统计方法采用SPSS13.0统计软件进行数据处理，计量资料以均数±标准差()表示，采用t检验，计数资料采用x2检验。P<0.05为差异有统计学意义。)
表一、两组临床症状疗效比较
Claims (9)
1.一种治疗冠心病的药品，由其特征在于所述药品由川芎、红花、地骨皮、槟榔、牡丹皮、枸杞六味中药组成。
2.根据权利要求1所述的药品，其特征在于所述药品的原料的重量比例为：川芎10-20g、红花8-15g、地骨皮20-40g、25-30g、槟榔6-15g、牡丹皮10-30g、枸杞10-20g。
3.根据权利要求2所述的药品，其特征在于所述药品的原料的重量比例为：川芎15g、红花10g、地骨皮25g、槟榔10g、牡丹皮20g、枸杞15g。
4.根据权利要求2所述的药品，其特征在于所述药品的原料的重量比例为：川芎15g、红花10g、地骨皮30g、槟榔8g、牡丹皮15g、枸杞15g。
5.根据权利要求2所述的药品，其特征在于所述药品的原料的重量比例为：川芎20g、红花8g、地骨皮20g、槟榔10g、牡丹皮30g、枸杞15g。
6.根据权利要求2-5任一所述的药品的活性成分制备方法，其特征在于所述活性成分的制备方法由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并得到水提物，加乙醇使含醇量为60％-85％，过滤，溶液除去溶剂得到提取物，干燥既得活性成分。
7.根据权利要求2-5任一所述的药品，其特征在于所述药品的制剂剂型为胶囊剂、片剂、丸剂、颗粒剂、口服液。
8.根据权利要求7所述的药品，其特征在于所述胶囊剂的制备方法由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为6-10倍量，煎煮时间为0.5-2小时，两次煎煮液合并，过滤，浓缩至60℃时测定相对密度为1.00-1.15的浓缩液，备用；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液1-5倍重量的淀粉、糊精或乳糖中的一种或两种，采用稠膏制粒法，进行制粒，在50-70℃下干燥，整粒，装胶囊，既得胶囊剂。
9.根据权利要求8所述的药品，其特征在于所述胶囊剂的制备方法由以下步骤制成：
(1)药材净选：取组方中药材分别净选，称取药材；
(2)药材提取：加水煎煮两次，两次加水量分别为8倍量，煎煮时间为1小时，两次煎煮液合并，过滤，浓缩至60℃时测定相对密度为1.10的浓缩液，备用；
(3)制粒、装胶囊：取步骤(2)的浓缩液，加入浓缩液3倍重量的淀粉，采用稠膏制粒法，进行制粒，在68℃下干燥，整粒，装胶囊，既得胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410521251.4A CN104306615A (zh) | 2014-09-30 | 2014-09-30 | 一种治疗冠心病的药品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410521251.4A CN104306615A (zh) | 2014-09-30 | 2014-09-30 | 一种治疗冠心病的药品及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306615A true CN104306615A (zh) | 2015-01-28 |
Family
ID=52362024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410521251.4A Pending CN104306615A (zh) | 2014-09-30 | 2014-09-30 | 一种治疗冠心病的药品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306615A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090190A (zh) * | 1993-01-19 | 1994-08-03 | 广东省石龙华南制药厂 | 治疗胸痹心痛的中药气雾剂及其制备方法 |
| CN1565548A (zh) * | 2003-06-18 | 2005-01-19 | 薛永新 | 治疗冠心病心绞痛的中药 |
| CN101647971A (zh) * | 2009-09-01 | 2010-02-17 | 宗翠红 | 一种内服用于治疗心血管病的中药配方 |
| CN102139025A (zh) * | 2010-02-03 | 2011-08-03 | 北京阜康仁生物制药科技有限公司 | 一种治疗冠心病的中药制剂及其制备方法 |
| CN102225100A (zh) * | 2011-06-04 | 2011-10-26 | 李现华 | 一种治疗心脑血管疾病的中药配方及其产品制备工艺 |
-
2014
- 2014-09-30 CN CN201410521251.4A patent/CN104306615A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1090190A (zh) * | 1993-01-19 | 1994-08-03 | 广东省石龙华南制药厂 | 治疗胸痹心痛的中药气雾剂及其制备方法 |
| CN1565548A (zh) * | 2003-06-18 | 2005-01-19 | 薛永新 | 治疗冠心病心绞痛的中药 |
| CN101647971A (zh) * | 2009-09-01 | 2010-02-17 | 宗翠红 | 一种内服用于治疗心血管病的中药配方 |
| CN102139025A (zh) * | 2010-02-03 | 2011-08-03 | 北京阜康仁生物制药科技有限公司 | 一种治疗冠心病的中药制剂及其制备方法 |
| CN102225100A (zh) * | 2011-06-04 | 2011-10-26 | 李现华 | 一种治疗心脑血管疾病的中药配方及其产品制备工艺 |
Non-Patent Citations (3)
| Title |
|---|
| 国家药典委员会: "《中华人民共和国药典 2005年版》", 31 January 2005, 化学工业出版社 * |
| 李柳骥: "冠心病心绞痛古今中医文献整理与研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
| 赵青主: "《小方子治大病》", 30 April 2014, 江西科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071128B (zh) | 一种治疗痛经的外用贴膏 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN103432390B (zh) | 一种治疗冠心病的药物及其制备方法 | |
| CN103330826B (zh) | 一种治疗肺阴虚的中药组合物 | |
| CN104873705A (zh) | 一种治疗冠心病心绞痛的药物组合物及其应用 | |
| CN104107321A (zh) | 一种治疗冠心病的中药组合物 | |
| CN103479969B (zh) | 一种治疗癫狂病的药物及其制备方法 | |
| CN103495009B (zh) | 一种治疗冠心病的中药 | |
| CN104758762A (zh) | 一种治疗肺痨的中药组合物 | |
| CN104013919A (zh) | 一种治疗心绞痛的中药 | |
| CN102133288B (zh) | 治疗心绞痛的中药制剂 | |
| CN103990078A (zh) | 一种用于治疗黄疸型肝炎的中药组合物 | |
| CN103919910A (zh) | 一种治疗冠心病的药物 | |
| CN102961561B (zh) | 一种治疗冠心病的中药组合物 | |
| CN102335370B (zh) | 一种加味逐瘀通脉药物组合物及其制备方法 | |
| CN103830552A (zh) | 一种治疗美尼尔氏病的中药组合物 | |
| CN103479895A (zh) | 一种舒心清脑中药组合物 | |
| CN114224998A (zh) | 一种治疗脾肾阳虚型功能性消化不良的中药组合物、制剂与应用 | |
| CN102988779A (zh) | 一种治疗高血压肾病的中药组合物及其制备方法和应用 | |
| CN102579804B (zh) | 一种治疗心绞痛的中药 | |
| CN101579509B (zh) | 治疗心律过早搏动的中药制剂 | |
| CN104117018A (zh) | 一种治疗冠心病的中药组合物 | |
| CN104306615A (zh) | 一种治疗冠心病的药品及其制备方法 | |
| CN103028088B (zh) | 一种治疗冠心病、心绞痛的中药组合物 | |
| CN103705868B (zh) | 一种治疗甲状腺功能亢进的药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150128 |